Image not found or type unknown

CURE Pharma gets USDEA nod to develop cannabinoid-based products

28 November 2018 | News

“This license enables CURE to translate the research findings from our collaboration with Technion – IsraelInstitute of Technology into potential treatments and expand our marketable product lines.”



CURE Pharmaceutical, an innovative drug delivery and development company, has secured a new registration with the Drug Enforcement Administration (DEA) as a manufacturer authorized to handle Schedule 1 controlled substances. With this license, CURE will develop and manufacture cannabinoid-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif.

“This license enables CURE to translate the research findings from our collaboration with Technion – Israel Institute of Technology into potential treatments and expand our marketable product lines,” said Jessica Rousset, Chief Operating Officer of CURE Pharmaceutical. “Building upon our recent licensing agreement with Canopy Growth, CURE is now in the perfect position to partner with companies in the pharmaceutical cannabinoid space looking for proprietary next-generation formulations.”

Schedule I substances are classified as drugs with no currently accepted medical use and a high potential for abuse, which has made it difficult for U.S.-based companies to develop and test products that will elucidate the pharmacological applications of cannabis.

CUREfilm technology is ideal for the delivery of cannabinoids as it offers increased bioavailability, ease and precision of dosing and greater palatability. Cannabinoids are chemical compounds found in plants, such as cannabis (phytocannabinoids), synthesized by cells of the human body (endocannabinoids) or synthesized in a laboratory (biosynthetic cannabinoids) that interact with the body’s endocannabinoid system. The endocannabinoid system is recognized as an

important modulatory system in the function of the brain, endocrine and immune tissues.